AI in Clinical Trial Design | Remington-Davis

Clinical research has always been defined by two competing pressures: the need for scientific rigor and the reality of human complexity. Every trial must be tight enough to produce defensible evidence and flexible enough to handle contact with real patients, real sites, and a real world that rarely behaves the way a protocol assumes.

For most of the modern era, the way researchers managed that tension was through more trial protocol — more criteria, more controls, more checkpoints. AI offers a different answer. But to understand where it fits and what it can realistically change, it helps to understand how clinical trial design got to where it is today.

Where Clinical Trial Design Started

The randomized controlled trial is younger as a formal methodology than most people assume. The Medical Research Council's 1948 study of streptomycin for tuberculosis established the core architecture that still governs clinical research today: randomization, a control group, blinding where possible, and pre-specified endpoints evaluated at a defined point in time.

A System Built Layer-by-Layer

What followed over the next several decades was a process of formalization. Each institution added rigor — and with it, complexity.

• 1960s–70s: The FDA's modern approval framework took shape, driven in part by the thalidomide disaster and its aftermath.
• 1990s: Good Clinical Practice guidelines emerged internationally, standardizing how trials should be designed, conducted, and reported.
• Ongoing: IRBs, informed consent requirements, adverse event reporting systems, and data monitoring committees were built out piece by piece.

Each layer served a real purpose. Together, they produced a system that had become expensive to run, slow to enroll, and difficult to course-correct once underway.

Where the Strain Shows

By the early 2000s, the average Phase III protocol had grown substantially in length and procedural demand compared to its predecessors. Studies required more visits, more assessments, more eligibility filters, and more documentation at every step. The intent was sound — better safety surveillance, more precise efficacy measurement, cleaner regulatory submissions. The operational consequence was a system operating near the limits of what a protocol-heavy, reactive model can sustain.

Where AI is Finding Its Way Into the Clinical Trial Lifecycle

Artificial intelligence is not arriving in clinical research as a clean replacement for the existing model. It is entering through the seams: the decision points where clinical teams have historically relied on precedent, manual review, and educated guesswork, and where the cost of being wrong is high.

The most meaningful clinical trial applications of machine learning and AI share a common characteristic: they change the quality of the assumptions that go into the design before enrollment begins. In doing so, they lay the groundwork for more efficient trials.

Before a Clinical Trial Launches

This is where AI is making the most immediate difference: stress-testing protocol assumptions while they are still cost-effective to fix.

• Eligibility criteria refinement: Many eligibility criteria are inherited from prior protocols without a fresh evaluation of whether they still serve their original purpose. AI tools that analyze real-world patient data, including unstructured clinical data in health records, can simulate how different thresholds affect the size and composition of the eligible population, surfacing restrictions that limit clinical trial recruitment without proportionate benefit.
• Site selection: Predictive modeling evaluates candidate sites against historical enrollment performance, patient population depth, protocol complexity, and competitive trial density. This produces assessments that reflect what a site is likely to contribute rather than what a sponsor hopes it will.
• Diversity planning: AI can identify mismatches between a proposed site's geographic footprint and the demographic distribution of the target patient population. Sponsors can then make adjustments before patient participation begins rather than after representation gaps have become a regulatory issue.
• Patient burden assessment: AI can model the cumulative burden of a protocol — visit frequency, procedural intensity, travel requirements — against retention patterns from comparable trials. Where burden is projected to drive dropout, sponsors can streamline assessments or incorporate decentralized clinical trial (or virtual trial) components before the protocol is finalized to reduce patient burden and enhance patient engagement throughout the trial.

Inside Running a Clinical Trial

Once enrollment begins, the focus shifts from design assumptions to real-time performance.

• Monitoring and data quality: Traditional monitoring operates on a lag — data is collected, reviewed periodically, and queries are raised weeks or months after the fact. Automated systems that flag inconsistencies and deviations as they occur compress that cycle and surface safety signals that periodic review might miss.
• Adaptive design: Bayesian statistical frameworks, now supported by FDA guidance, enable trials to adjust sample sizes, drop underperforming arms, or refine patient selection criteria in real-time without compromising the primary analysis’s statistical integrity. AI makes those adjustments computationally tractable at the scale of a modern trial.
  

What AI Has Not Changed in Clinical Research

Randomization, blinding, pre-specified endpoints, regulatory oversight, and the primacy of human clinical judgment remain intact. The tools are getting sharper. The structure is still standing.

Where the Field Is Headed

The next phase for AI in clinical research is likely to be less about individual tools and more about integration. It's a matter of connecting data that sits in separate systems across sites, sponsors, regulators, and health systems into something that supports continuous learning across the full development lifecycle.

Technologies Taking Shape Now

• Digital twins and synthetic control arms: Computational models of individual patients or populations built from biological and clinical data allow sponsors to simulate how an enrolled population would respond before the first trial participant is screened. Synthetic control arms generated from these models are beginning to reduce the need for large placebo groups in settings where withholding active treatment raises ethical concerns.
• Genomics-integrated design: Trials built around AI-identified molecular subtypes are producing cleaner efficacy signals in oncology and immunology. The long-term implication is a shift from disease-category-based design toward biology-based design — studies defined by the specific mechanism a therapy is targeting and the patient profile most likely to respond.
• Generative AI in trial operations: Protocol drafting, informed consent preparation, and regulatory submission support are beginning to benefit from large language model tools that reduce the time and cost of study startup and documentation. These are not the highest-stakes applications, but they are the most immediately scalable.

The Constraint the Field Has Not Solved

AI models are only as reliable as the datasets they learn from. Clinical research data remains largely siloed, inconsistently structured, and demographically skewed toward populations that have historically been overrepresented in trials. Two approaches are being pursued in parallel:

• Federated learning: Training models across institutions without centralizing patient records, preserving privacy while expanding the data available for analysis.
• Diverse patient recruitment and biorepository development: Building the underlying data infrastructure that makes AI outputs representative and generalizable across the populations trials are meant to serve.

Neither is a fast fix, and both are necessary.

Projecting the Future of AI in Drug Development

The next decade will produce a gradual shift from a process that is largely reactive to one that is more predictive. That shift has already started. The question for pharmaceutical companies and research sites alike is how quickly they can build the infrastructure and the institutional experience to take advantage of it and support clinical trial success.

Frequently Asked Questions

Does artificial intelligence change the fundamental structure of a clinical trial?

Not in its current form. Randomization, blinding, pre-specified endpoints, and regulatory oversight remain the foundation of trial design. AI changes the quality of the assumptions that go into a protocol and compresses the feedback cycle during execution, but it doesn't replace the architecture that produces regulatory-grade evidence.

Where in the trial lifecycle does AI have the most impact today?

The most immediate impact is at the design stage, before enrollment begins. Eligibility criteria simulation, site selection modeling, and diversity planning are the areas where AI is most widely deployed and where the cost of getting things wrong is highest. Monitoring and adaptive design applications are maturing quickly, but require more institutional infrastructure to deploy effectively.

What is an adaptive trial design, and how does AI support it?

An adaptive trial allows pre-specified modifications to protocol parameters such as sample size, dosing arms, or patient selection criteria in response to accumulating interim data, without compromising the statistical validity of the primary analysis. AI supports adaptive design by making the continuous data analysis required for these modifications computationally feasible at the scale of a modern trial. The FDA has issued guidance supporting Bayesian adaptive frameworks, giving sponsors a clearer regulatory pathway for using them.

What is a digital twin in clinical research?

A digital twin is a computational model of a patient or patient population, built from biological, demographic, and clinical data, used to simulate how that population would respond to a treatment under defined trial conditions. In practice, digital twins are used to stress-test protocol assumptions before enrollment begins and, in some indications, to generate synthetic control arms that reduce or eliminate the need for traditional placebo groups.

What is the biggest obstacle to AI adoption in clinical trials?

Data quality and availability. AI models are only as reliable as the datasets they learn from, and clinical research data is still largely siloed across institutions, inconsistently structured, and not representative of the full diversity of patient populations. Solving this problem requires both technical approaches and sustained investment in diverse recruitment infrastructure. Most organizations are still in early stages on both fronts.